Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarechale Cap. Regulatory News (MAC)

Share Price Information for Marechale Cap. (MAC)

Share Price is delayed by 15 minutes
Get Live Data
7.00    0.45 (6.87%)
Bid:
6.50
Ask:
7.50
Spread: 1.00 (15.385%)
Market Cap: £8.36m
MAC Live PriceLast checked at - London Stock Exchange

Intraday Marechale Cap. Share Chart

Half-year Report

19 Jan 2026 12:15

Marechale Capital Plc - Half-year Report

Marechale Capital Plc - Half-year Report

PR Newswire

LONDON, United Kingdom, January 19

19 January 2026

Marechale Capital plc

("Marechale Capital", “Marechale” or the "Company")

Half-yearly Results

Marechale Capital plc, an established City of London based corporate finance house with a long-term track record and a strong reputation for advising and financing high growth consumer brands, leisure, clean energy, mineral extraction and technology companies, announces its unaudited half-yearly results for the six months ended 31 October 2025 (the “Period”).

Chairman’s Statement

A difficult first half to the Company’s year has been a feature of recent years, with 2025 being no exception, particularly with the SME market being challenging. However, the market started to pick up in November 2025, and there has been a healthy new business pipeline developing in recent months.

During the six months ended 31 October 2025, the Company generated a gross profit of £55,310 (2024: £103,468) and delivered an operating loss of £177,066 (2024: loss of £138,485 ), resulting in an overall loss before tax of £176,515 (2024: loss of £178,261).

The Company’s balance sheet shows a net asset value of £3,063,198 (2024: £3,183,537), representing 2.56p (2024: 3.01p) of value per share in issue. The Board remains positive about the investments that it holds in its client companies, and in particular its core investment in Weardale Lithium.

Whilst there have been delays in completing some advisory projects during the Period, on a positive note, Marechale has in the last few months completed both debt and equity growth round transactions for Wright Brothers, the UK’s leading premium fish wholesaler and restaurant operator, KBH, one of the UK’s leading ‘out of home’ media companies on the UK’s railways and cinemas, Weardale Lithium, which has received planning for the UK’s first Direct Lithium Extraction plant and Chestnut Inns, one of the UK’s leading premium inn operators.

Cash at bank as at 31 October 2025 was £228,593 (2024: £223,700). However, in the months since the end of the Period, and based on the recent transactions that Marechale has completed, the Company has grown its cash at bank to £312,000 as at 14 January 2026.

The Board is working on a number of initiatives to create further value for shareholders over and above its core investment portfolio and corporate finance projects, including working with various potential businesses and individuals.

This plan to continue to develop Marechale’s strategic partnerships in order to enhance shareholder value, and develop new funding partners alongside its traditional investor relationships, has culminated in the successful completion of a placing in Marechale shares in October (as previously announced); this brought in two new strategic investors as well, in addition to all the Company’s directors investing too.

Marechale Capital continues to see interesting corporate finance and advisory projects; the Board believes despite the challenges of the last few years, that the SME market is looking more positive, and that there is a recognition of value in UK growth companies, particularly with new initiatives for the AIM markets, the Enterprise Investment Scheme (EIS), and the move to encourage more private and institutional funding into smaller UK companies.

Whilst the current economic climate is difficult, Marechale Capital remains diligent and is convinced that there will continue to be good advisory and investment opportunities in its core hospitality, renewable, clean energy and technology sectors over the short to medium term, where the Company can generate more value enhancing warrant and founding equity holdings alongside advisory cash fees. The Board is also hoping to agree terms on further strategic partnerships, and is in a number of advanced conversations with different parties.

Mark Warde-Norbury

Chairman

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

For further information please contact:

Marechale Capital

Mark Warde-Norbury / Patrick Booth-Clibborn

Tel: +44 (0)20 7628 5582

Cairn Financial Advisers LLP

Jo Turner / Sandy Jamieson

Tel: +44 (0)20 7213 0880

Income Statement (unaudited)
6 months ended 31 October 2025 2024
£ £
Revenue 111,932 148,500
Cost of sales (56,622) (45,032)
Gross profit 55,310 103,468
Administrative expenses (232,376) (241,953)
Operating loss (177,066) (138,485)
Exceptional credit 600 10,316
Loss on disposal of investments - (49,837)
Interest paid (49) (255)
(Loss) before tax (176,515) (178,261)
Taxation - -
(Loss) after tax (176,515) (178,261)
(Loss) per share
(Pence) (Pence)
- Basic (0.17) (0.17)
- Diluted (0.17) (0.17)

Balance Sheet (unaudited)
As at 31 October 31 October
2025 2024
Current assets
Available for sale investments 2,807,829 2,939,660
Trading investments 58,800 49,953
Trade and other receivables 91,172 52,856
Cash and cash equivalents 228,593 223,712
3,186,394 3,266,181
Current liabilities

Trade and other payables

PAYE

Bounce-back Loan

(110,811)

(4,885)

(7,500)

(54,338)

(10,806)

(10,000)

Total current liabilities (123,196) (75,144)
Net current assets 3,063,198 3,191,037
Bounce-back Loan – long-term - (7,500)
Net assets 3,063,198 3,183,537
Equity
Capital and reserves attributable to equity shareholders

Share capital

Share premium

955,530

575,790

847,530

481,290

Reserve for own shares (50,254) (50,254)
Retained profits/ (losses) 1,403,817 1,739,397
Reserve for share based payments 178,315 165,574
3,063,198 3,183,537
Cash Flow Statement (unaudited)
6 months ended 31 October 31 October
2024
£
Net cash from operating activities
Loss after tax (176,515) (178,261)
Reverse exceptional credits (600) (10,316)
Loss of disposal of investments - 49,837

Provision for share based payments

Reverse interest paid

-

49

15,406

255

Operating cash flows before movements in working capital (177,066) (123,079)
Movement in working capital
Decrease/ (increase) in receivables 13,852 (7,950)
(Decrease)/ Increase in payables (17,795) 3,108
Net movement in working capital (3,942) (4,842)
Operating cash out-flow (181,009) (127,921)
Investment activities
Expenditure on available for sale investments - -
Proceeds from sale of investments and options - 108,692
Cash flow from investing activities - 108,692

Financing

Share Capital

Bounce-back Loan repayments

Interest paid

Net financing

202,500

(5,000)

(48)

197,452

-

(5,000)

(255)

(5,255)

Net Increase / (decrease) in cash and cash equivalents 16,443 (24,484)
Cash and cash equivalents at start of the period 212,150 248,196
Cash and cash equivalents at end of the period 228,593 223,712
Increase / (decrease) in cash and cash equivalents 16,443 (24,484)

This financial information has been prepared in accordance with IFRS and International Financial Reporting Interpretations Committee ('IFRIC') interpretations adopted by the European Union, and with those parts of the Companies Act 2006 applicable to companies reporting under IFRS, with the prior period being reported on the same basis.



Date   Source Headline
9th Nov 20112:50 pmRNSHolding(s) in Company
22nd Sep 201111:20 amRNSResult of AGM
20th Sep 201110:03 amRNSDirector/PDMR Shareholding
25th Aug 20119:46 amRNSFinal Results
18th Apr 20111:44 pmRNSDirector/PDMR Shareholding
14th Apr 20112:16 pmRNSHolding(s) in Company
12th Apr 20117:00 amRNSDirectorate Change
31st Mar 20113:28 pmRNSIssue of Equity
29th Mar 20113:17 pmRNSDirectorate Appointment & Dealing
28th Mar 20113:39 pmRNSDirector/PDMR Shareholding
16th Mar 20119:20 amRNSDirector/PDMR Shareholding
25th Feb 20113:46 pmRNSHolding(s) in Company
9th Feb 20112:02 pmRNSDirector/PDMR Shareholding
19th Jan 20111:34 pmRNSDirector/PDMR Shareholding
13th Jan 20114:19 pmRNSHolding(s) in Company
11th Jan 201112:27 pmRNSDirector/PDMR Shareholding
15th Dec 201012:00 pmRNSHalf Yearly Report
29th Sep 20103:06 pmRNSResult of AGM
22nd Sep 201010:34 amRNSDirector/PDMR Shareholding
7th Sep 201012:00 pmRNSFinal Results and Notice of General Meeting
17th Mar 20109:00 amRNSChange of Adviser
22nd Feb 20103:15 pmRNSResult of GM
12th Feb 201012:00 pmRNSDirector/PDMR Shareholding
4th Feb 201011:00 amRNSDirector/PDMR Shareholding
29th Jan 201012:00 pmRNSNotice of General Meeting
12th Jan 20107:00 amRNSApplication for New Ordinary Shares
23rd Dec 20092:31 pmRNSHalf Yearly Report
17th Dec 20095:15 pmRNSResult of AGM
7th Dec 200912:28 pmRNSHoldings in Company / Directors Dealings
23rd Nov 20097:00 amRNSAcquisition and AGM
23rd Oct 20099:17 amRNSHolding in Company
15th Oct 20092:41 pmRNSChange of Name of Nominated Adviser and Broker
30th Sep 20094:00 pmRNSAnnual Report & Accounts
18th Sep 20097:00 amRNSNotifiable Interests
18th Sep 20097:00 amRNSHolding in Company
28th Aug 20092:30 pmRNSAcquisition of Whim Gully Capital LLP
28th Aug 20092:30 pmRNSPreliminary Results and Notice of General Meeting
21st Jul 20097:00 amRNSDisposal
6th Aug 200810:59 amRNSDirector/PDMR Shareholding
23rd Jun 20087:00 amRNSAppointment of joint broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.